Premium
Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature
Author(s) -
López Verónica,
Molina Inmaculada,
Monteagudo Carlos,
Jordá Esperanza
Publication year - 2011
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2010.04728.x
Subject(s) - ribavirin , medicine , pegylated interferon , sarcoidosis , dermatology , immunology , virus , hepatitis c virus
Sarcoidosis is a multisystem granulomatous disease that affects multiple organs in adults between 20 and 50 years old. Interferon alpha (IFN‐α) is an immunomodulator that has been used in a wide range of diseases, including hepatitis C virus infection, multiple sclerosis, and other types of neoplasias, including leukemia, lymphoma, Kaposi’s sarcoma, and melanoma. Standard IFN‐α‐induced sarcoidosis has been reported, but there are few reports of cutaneous sarcoidosis with pegylated IFN‐α therapy. We present a new case of cutaneous sarcoidosis after treatment with pegylated IFN, and a review of the literature.